CGEMS
The Cancer Genetic Markers of Susceptibility (CGEMS) is a three-year, $14 million initiative that will identify genetic alterations that make people susceptible to prostate and breast cancer.
Gilles Thomas M.D., Ph.D., Lead NCI Scientist
The Lead NCI Scientist directs the scientific analysis of the Cancer Genetic Markers of Susceptibility (CGEMS) project. The Lead NCI Scientist provides scientific direction for the quality assessment/quality control, assessment of population heterogeneity, analysis and publication of genome-wide association studies (GWAS), such as CGEMS (in breast cancer and prostate cancer) and PanScan (pancreatic cancer).
Kevin B. Jacobs GWAS Operations and Analysis Lead
The GWAS Operations and Analysis Lead is responsible for operations and primary analysis of the Cancer Genetic Markers of Susceptibility (CGEMS) project. The GWAS Operations and Analysis Lead is also responsible for architecting the data and software architecture to manage the billions of genetic data points generated by genome-wide association studies (GWAS), used to support CGEMS (in breast cancer and prostate cancer), PanScan (pancreatic cancer), and other GWAS efforts.
